Avaleht › Eesnäärmevähk › Texas
Eesnäärmevähk kliinilised uuringud osariigis Texas
115 uuringut haiguse Eesnäärmevähk jaoks otsivad osalejaid osariigis Texas.
Linnad osariigis Texas
- Houston76 uuringut
- Dallas36 uuringut
- San Antonio28 uuringut
- Austin15 uuringut
- Fort Worth9 uuringut
- The Woodlands6 uuringut
- Richardson6 uuringut
- League City4 uuringut
- Sugar Land4 uuringut
- Irving4 uuringut
- Arlington3 uuringut
Ametlik uuringutekst (inglise keeles)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- ja veel 2
VärbamineFaas 1/2
Vanused 12 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT04585750Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- ja veel 1
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 2. okt 2026 · NCT06931340Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Covenant Medical Center-Lakeside, Lubbock
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 2. okt 2026 · NCT07200830A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT06465069Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
Vanused 40–75 · Kõik sood · Uuendatud 2. okt 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- ja veel 2
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT06632977A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 1. okt 2026 · NCT06172478Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- ja veel 1
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 30. sept 2026 · NCT03866382Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
- Urology Austin, Austin
VärbamineFaas 4
Vanused 18 ja vanemad · Mehed · Uuendatud 29. sept 2026 · NCT07569926A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
VärbamineFaas 1
Vanused 18 ja vanemad · Mehed · Uuendatud 28. sept 2026 · NCT06095089Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
- Urology Austin, Austin
Värbamine
Vanused 18 ja vanemad · Mehed · Uuendatud 28. sept 2026 · NCT06496256DESTINY-PANTUMOUR04
- Research Site, Dallas
VärbamineVaatlusuuring
Vanused 18–130 · Kõik sood · Uuendatud 25. sept 2026 · NCT07124000Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
- The University of Texas M. D. Anderson Cancer Center, Houston
VärbamineVarajane 1. faas
Vanused 18 ja vanemad · Mehed · Uuendatud 25. sept 2026 · NCT06759701Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer
- M D Anderson Cancer Center, Houston
Värbamine
Vanused 18 ja vanemad · Mehed · Uuendatud 25. sept 2026 · NCT07377006Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Research Site, Houston
VärbamineFaas 1/2
Vanused 18–130 · Mehed · Uuendatud 25. sept 2026 · NCT07181161Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- NEXT Oncology, Austin
- MD Anderson Cancer Center, Houston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Mehed · Uuendatud 25. sept 2026 · NCT06800313A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Texas Oncology - Central/South Texas ( Site 8003), Austin
- Texas Oncology - DFW ( Site 8001), Dallas
- Texas Oncology - Gulf Coast ( Site 8002), Houston
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT06136650This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital, Dallas
- University of Texas Southwestern Simmons Cancer Center - Redbird, Dallas
- ja veel 5
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 24. sept 2026 · NCT07028853A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- START Dallas-Fort Worth, Fort Worth
- NEXT Houston, Houston
- NEXT Oncology, San Antonio
VärbamineFaas 1
Vanused 18 ja vanemad · Mehed · Uuendatud 24. sept 2026 · NCT07719361Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Texas Oncology, Dallas
- Urology San Antonio, San Antonio
VärbamineFaas 2/3
Vanused 18–100 · Mehed · Uuendatud 22. sept 2026 · NCT06780670A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- Mary Crowley Cancer Research, Dallas
VärbamineFaas 1
Vanused 18 ja vanemad · Mehed · Uuendatud 22. sept 2026 · NCT07570979A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07114601A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- The Center for Cancer and Blood Disorders, Arlington
- University of Texas Southwestern Medical Center, Dallas
- Renovatio Clinical, Houston
- ja veel 2
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 22. sept 2026 · NCT07213674Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Urology Austin, Lakeway
- Urology San Antonio, San Antonio
- Woodlands Cancer Institute American Oncology Partners, The Woodlands
VärbamineFaas 3
Vanused 18–100 · Mehed · Uuendatud 22. sept 2026 · NCT06855277A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Austin
- Research Site, Austin
- Research Site, Houston
- ja veel 2
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 18. sept 2026 · NCT06952803Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
- MD Anderson Cancer Center, Houston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Mehed · Uuendatud 18. sept 2026 · NCT06085729High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
VärbamineFaas 2
Vanused 18 ja vanemad · Mehed · Uuendatud 17. sept 2026 · NCT05011383A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Parkland Health & Hospital System ( Site 0069), Dallas
- UT Southwestern Medical Center ( Site 0039), Dallas
- University of Texas-MD Anderson Cancer Center ( Site 0055), Houston
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 17. sept 2026 · NCT06925737Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
- University of Texas MD Anderson Cancer Center, Houston
- Next Oncology - Dallas, Irving
VärbamineFaas 1
Vanused 18 ja vanemad · Mehed · Uuendatud 15. sept 2026 · NCT07493512Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Urology Partners of North Texas (UPNT), Arlington
Värbamine
Vanused 18 ja vanemad · Mehed · Uuendatud 14. sept 2026 · NCT06511141Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Urology Austin, PLLC - Research Department, Austin
- Urology Clinics of North Texas, Dallas
- University of Texas Southwestern Medical Center, Dallas
- ja veel 1
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 11. sept 2026 · NCT06056830Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- MD Anderson in The Woodlands, Conroe
- Brooke Army Medical Center, Fort Sam Houston
- UT MD Anderson Cancer Center, Houston
- ja veel 3
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 10. sept 2026 · NCT05946213Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- Investigational Site Number: 401, Houston
VärbamineFaas 1
Vanused 18 ja vanemad · Mehed · Uuendatud 10. sept 2026 · NCT05997615A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- UT MD Anderson, Houston
- NEXT Oncology, San Antonio
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. sept 2026 · NCT06440005A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- SCRI Oncology Partners, Nashville
VärbamineFaas 1
Vanused 18 ja vanemad · Mehed · Uuendatud 8. sept 2026 · NCT05800665Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
- SCRI at Mary Crowley, Dallas
VärbamineFaas 1
Vanused 18 ja vanemad · Mehed · Uuendatud 3. sept 2026 · NCT07545811A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- Urology Clinics Of North Texas, Dallas
- Urology Partners of North Texas (UPNT), Fort Worth
- Houston Metro Urology (HMU), Houston
VärbamineFaas 3
Vanused 18 ja vanemad · Mehed · Uuendatud 3. sept 2026 · NCT07723248Prostate Active Surveillance Study
- University of Texas Health Science Center, San Antonio, San Antonio
VärbamineVaatlusuuring
Vanused 21 ja vanemad · Mehed · Uuendatud 2. sept 2026 · NCT00756665A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
- University of Texas Southwestern Medical Center, Dallas
VärbamineFaas 2
Vanused 18 ja vanemad · Mehed · Uuendatud 31. aug 2026 · NCT05726292Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- START San Antonio, San Antonio
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 27. aug 2026 · NCT06582017Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.